Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2024-10-17 4:01 pm Purchase | 13D | MorphoSys AG MOR | NOVARTIS AG NVS | 37,716,423 100.000% | 2,108,003 (+5.92%) | View |
2024-08-15 4:30 pm Purchase | 13D | MorphoSys AG MOR | NOVARTIS AG NVS | 35,608,420 94.550% | 1,270,611 (+3.70%) | View |
2024-06-21 4:30 pm Unchanged | 13D | MorphoSys AG MOR | NOVARTIS AG NVS | 34,337,809 91.170% | 0 (Unchanged) | View |
2024-06-17 4:30 pm Purchase | 13D | MorphoSys AG MOR | NOVARTIS AG NVS | 34,337,809 91.170% | 641,331 (+1.90%) | View |
2024-06-10 4:30 pm Purchase | 13D | MorphoSys AG MOR | NOVARTIS AG NVS | 33,696,478 89.470% | 3,725,565 (+12.43%) | View |
2024-05-28 4:30 pm Purchase | 13D | MorphoSys AG MOR | NOVARTIS AG NVS | 29,970,913 79.580% | 25,610,813 (+587.39%) | View |
2024-04-18 2:33 pm Purchase | 13D | MorphoSys AG MOR | NOVARTIS AG NVS | 4,360,100 11.560% | 4,360,100 (New Position) | View |
2024-02-02 2:18 pm Purchase | 13G | NOVARTIS AG ADS NVS | BlackRock Inc. BLK | 139,392,071 6.100% | 8,398,901 (+6.41%) | View |
2023-02-01 4:54 pm Sale | 13G | NOVARTIS AG ADS NVS | BlackRock Inc. BLK | 130,993,170 5.400% | -7,074,544 (-5.12%) | View |
2022-02-04 4:12 pm Purchase | 13G | NOVARTIS AG ADS NVS | BlackRock Inc. BLK | 138,067,714 5.700% | 138,067,714 (New Position) | View |
2020-08-19 4:31 pm Unchanged | 13G | XOMA Royalty Corp XOMA | NOVARTIS AG NVS | 539,131 4.900% | 0 (Unchanged) | View |